Celcuity+Logo.jpg
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
April 04, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that...
MacroGenics-Logo-(transparent-background).png
MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures
April 03, 2024 16:30 ET | MacroGenics, Inc.
Early interim safety data from Phase 2 TAMARACK study, including comparison to retrospective analysis from Phase 1 study, as submitted in ASCO abstractCompany plans to provide updated interim data,...
22157.jpg
Global Interventional Oncology Devices Market Targets Growth to $3.25 Billion by 2028
March 26, 2024 18:10 ET | Research and Markets
Dublin, March 26, 2024 (GLOBE NEWSWIRE) -- The "Interventional Oncology Devices Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Expansion Driven by...
Fibrogen_US_Primary_logo_RGB_M01.jpg
FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference
March 26, 2024 07:00 ET | FibroGen, Inc.
SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...
22157.jpg
Community Oncology Services Global Market Report 2024
March 21, 2024 18:54 ET | Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Community Oncology Services Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The community oncology services...
Celcuity+Logo.jpg
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call
March 20, 2024 07:05 ET | Celcuity Inc.
MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it...
22157.jpg
Global Oncologists Market Report 2024: Precision Medicine and Therapeutic Advancements Drive Expansion to $22.72 Billion by 2028
March 13, 2024 12:11 ET | Research and Markets
Dublin, March 13, 2024 (GLOBE NEWSWIRE) -- The "Oncologists Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering.The global oncologists market has grown steadily in...
Global Interventional Oncology Market
Global Interventional Oncology Market Anticipates Explosive Growth, Forecasted at $8.06 Billion by 2034 - Regional Insights for Products, Cancer Types, and End-users
March 12, 2024 12:39 ET | Research and Markets
Dublin, March 12, 2024 (GLOBE NEWSWIRE) -- The "Global Interventional Oncology Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. The global...
CURIUM ANNUNCIA LE P
CURIUM ANNUNCIA LE PRIME DOSI COMMERCIALI IN ITALIA DI PYLCLARI® - UN INNOVATIVO TRACCIANTE PET 18F-PSMA INDICATO NEI PAZIENTI CON TUMORE ALLA PROSTATA
March 07, 2024 08:51 ET | Curium
Parigi, Francia, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, leader mondiale nella medicina nucleare, ha annunciato oggi la vendita delle prime dosi commerciali di PYLCLARI® in Italia. PYLCLARI®...
Curium Announces Fir
Curium Announces First Commercial Doses in Italy of PYLCLARI® – An Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
March 07, 2024 08:51 ET | Curium
PARIS, March 07, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that the first commercial doses of PYLCLARI® have been sold in Italy. PYLCLARI® (INN:...